The Nifty Pharma index remained under sharp pressure on Wednesday, falling over 1.5 percent, with heavyweight drugmakers Sun Pharma, Cipla and Dr Reddy's Laboratories trading lower after US President Donald Trump unveiled a phased tariff plan for imported generic medicines. Cipla and Dr Reddy's were also among the top losers on the Nifty 50, as the announcement raised concerns over the long-term outlook for Indian drugmakers with significant exposure to the US market.